1493 related articles for article (PubMed ID: 25839441)
1. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
2. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
[TBL] [Abstract][Full Text] [Related]
3. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
9. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
Park MY; Kim HS; Woo SJ; Kim CH; Park JS; Sohn HJ; Kim HJ; Oh ST; Kim TG
Eur J Immunol; 2008 Aug; 38(8):2106-17. PubMed ID: 18624349
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
11. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
Van Meirvenne S; Dullaers M; Heirman C; Straetman L; Michiels A; Thielemans K
Mol Ther; 2005 Nov; 12(5):922-32. PubMed ID: 16257383
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination.
Pedersen AE; Thorn M; Gad M; Walter MR; Johnsen HE; Gaarsdal E; Nikolajsen K; Buus S; Claesson MH; Svane IM
Scand J Immunol; 2005 Feb; 61(2):147-56. PubMed ID: 15683451
[TBL] [Abstract][Full Text] [Related]
14. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
Salem ML
Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
[TBL] [Abstract][Full Text] [Related]
15. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
16. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
17. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
19. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
[TBL] [Abstract][Full Text] [Related]
20. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
